BRIEF-Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement
Feb 14 ChemoCentryx Inc
* Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases
* ChemoCentryx Inc - vifor pharma has gained rights to commercialize avacopan in Asia, including Japan and Middle-East
* ChemoCentryx Inc - ChemoCentryx retains all rights in united states and china
* ChemoCentryx Inc - agreement gives Vifor Pharma rights to commercialize Avacopan for orphan, rare renal diseases in all markets outside U.S. , China
* ChemoCentryx Inc - will receive an upfront cash commitment of usd 20 million in return for new rights, plus tiered double-digit royalties on potential net sales
* ChemoCentryx Inc - upfront cash commitment is in addition to usd 85 million upfront paid under original May 2016 licensing agreement Source text for Eikon: Further company coverage: